Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding

Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring
Laetitia LemoineAgneta Nordberg

Abstract

Ligands targeting tau for use with positron emission tomography have rapidly been developed during the past several years, enabling the in vivo study of tau pathology in patients with Alzheimer's disease and related non-Alzheimer's disease tauopathies. Several candidate compounds have been developed, showing good in vitro characteristics with respect to their ability to bind tau deposits; off-target binding, however, has also been observed. In this short commentary, we briefly summarize the available in vivo and in vitro evidence pertaining to their off-target binding and discuss the different approaches that are needed for the future development of tau positron emission tomography tracers.

References

Jan 5, 2011·Nature Reviews. Neuroscience·Lars M Ittner, Jürgen Götz
Feb 16, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Chun-Fang XiaHartmuth C Kolb
Oct 28, 2015·Annals of Neurology·Keith A JohnsonReisa Sperling
Nov 7, 2015·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Ryuichi HaradaYukitsuka Kudo
Jan 12, 2016·Biomolecules·Ryuichi HaradaYukitsuka Kudo
Mar 5, 2016·Neuron·Michael SchöllWilliam J Jagust
May 28, 2016·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Eric D HostetlerJeffrey L Evelhoch
Jun 15, 2016·Acta Neuropathologica Communications·Val J LoweMelissa E Murray
Jun 18, 2016·Annals of Neurology·Milos D IkonomovicWilliam E Klunk
Jun 21, 2016·Annals of Neurology·Hanna ChoChul Hyoung Lyoo
Nov 1, 2016·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A IshikiK Furukawa
Nov 18, 2016·Molecular BioSystems·Jennifer A E PayneMax J Cryle
Dec 21, 2016·Annals of Neurology·Marta MarquiéTeresa Gómez-Isla
Jan 15, 2017·Brain : a Journal of Neurology·Maiko OnoMakoto Higuchi
Feb 6, 2017·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Sarah CoakeleyAntonio P Strafella
Feb 22, 2017·Molecular Neurodegeneration·Laure Saint-AubertAgneta Nordberg
Apr 1, 2017·Alzheimer's Research & Therapy·Kok Pin NgPedro Rosa-Neto
Apr 26, 2017·Movement Disorders : Official Journal of the Movement Disorder Society·Shunsuke KogaDennis W Dickson
Jul 6, 2017·Nature·Anthony W P FitzpatrickSjors H W Scheres
Oct 14, 2017·Alzheimer Disease and Associated Disorders·Hyon LeeYoung Noh
Dec 27, 2017·Movement Disorders : Official Journal of the Movement Disorder Society·Céline VermeirenMichel Gillard

❮ Previous
Next ❯

Citations

Feb 16, 2019·Acta Neuropathologica Communications·Santosh JadhavNorbert Zilka
Mar 29, 2019·European Journal of Nuclear Medicine and Molecular Imaging·N Arul MuruganAgneta Nordberg
May 14, 2019·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Daniela PeraniUNKNOWN IMBI Brain Imaging Working Group
Feb 6, 2020·Neurology·Melissa McSweeneyUNKNOWN PREVENT-AD Research Group
May 15, 2020·Alzheimer's Research & Therapy·Alexander J EhrenbergRoss W Paterson
Aug 14, 2020·EMBO Molecular Medicine·Michael EwersNicolai Franzmeier
Apr 23, 2020·European Journal of Nuclear Medicine and Molecular Imaging·Leonie BeyerMatthias Brendel
Sep 5, 2020·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Eric McDadeAnn Marie Hake
Oct 2, 2019·Frontiers in Aging Neuroscience·Sonja SchöneckerJohannes Levin
Nov 4, 2020·Brain : a Journal of Neurology·David N Soleimani-MeigooniGil D Rabinovici
Nov 24, 2020·Molecular Neurodegeneration·L LemoineA C Granholm
Nov 29, 2020·Science Advances·Nicolai FranzmeierMichael Ewers
Jan 19, 2020·Nature Communications·Nicolai FranzmeierUNKNOWN Alzheimer’s Disease Neuroimaging Initiative (ADNI)
Jan 12, 2021·Frontiers in Neuroscience·Amelie SchäferEllen Kuhl
Jan 26, 2020·Nuclear Medicine and Biology·Severin MairingerClaudia Kuntner
Apr 28, 2021·Molecular Neurodegeneration·Tatsuhiro TeradaPedro Rosa-Neto
May 1, 2021·Nature Medicine·Jacob W VogelOskar Hansson
May 6, 2021·Movement Disorders : Official Journal of the Movement Disorder Society·Carla PalleisGünter U Höglinger
May 14, 2021·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Rik Ossenkoppele, Oskar Hansson
Jun 2, 2021·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Nicolai FranzmeierUNKNOWN Alzheimer's Disease Neuroimaging Initiative (ADNI)* and the Swedish BioFINDER study
Aug 3, 2021·Frontiers in Physiology·Amelie SchäferUNKNOWN Alzheimer's Disease Neuroimaging Initiative (ADNI)
Aug 14, 2021·Alzheimer's Research & Therapy·Davina BielUNKNOWN Alzheimer’s Disease Neuroimaging Initiative (ADNI)
Jan 4, 2020·ACS Chemical Neuroscience·Vasko KramerPatrick J Riss
Jul 25, 2019·ACS Chemical Neuroscience·Lindsey R DrakePeter J H Scott
Sep 29, 2021·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Claire SextonMaria C Carrillo

❮ Previous
Next ❯

Methods Mentioned

BETA
electron microscopy

Related Concepts

Related Feeds

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

Related Papers

Molecular Neurodegeneration
Laure Saint-AubertAgneta Nordberg
© 2022 Meta ULC. All rights reserved